This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gonzalez-Angulo, A. M. Articles by Hortobágyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Gonzalez-Angulo, A. M. Articles by Hortobágyi, G. N.

Breast Cancer

Trends for Inflammatory Breast Cancer: Is Survival Improving?

Departments of ^aBreast Medical Oncology, ^bGynecology Oncology, ^cBiostatistics and Applied Mathematics, ^dSurgical Oncology, ^eRadiation Oncology, and ^fPathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Key Words. Inflammatory breast cancer • Trends • Survival • Prognosis

Correspondence: Ana M. Gonzalez-Angulo, M.D., Department of Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA. Telephone: 713-792-2817; Fax: 713-794-4385; e-mail: agonzalez{at}mdanderson.org

Received February 15, 2007; accepted for publication May 22, 2007.

The purpose of this study was to evaluate whether the survival of women with inflammatory breast cancer (IBC) treated at our institution has improved over the past 30 years. Three-hundred ninety-eight patients with IBC were treated between 1974 and 2005. Patient characteristics and outcomes were tabulated and compared among decades of diagnosis. Survival outcomes were estimated with the Kaplan-Meier product limit method and compared among groups with the log-rank statistic. Cox proportional hazards models were fit to determine the association between year of diagnosis and survival outcomes after adjustment for patient and disease characteristics and treatments received. The median follow-up was 5.8 years (range, 0.3–23.8 years). There were 238 recurrences and 236 deaths. The median recurrence-free survival (RFS) duration was 2.3 years and the median overall survival (OS) time was 4.2 years. In the models for RFS and OS, after adjustment for patient and disease characteristics, increasing year of diagnosis was not associated with a decrease in the risk for recurrence (hazard ratio, [HR], 1.00; 95% confidence interval [CI], 0.97–1.04) or death (HR, 0.97; 95% CI, 0.94–1.01). Our data show that there has not been an important change in the prognosis of patients with IBC in the last 30 years. Clinical trials focusing on the management of this aggressive disease are warranted.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				A. Molckovsky, B. Fitzgerald, O. Freedman, R. Heisey, and M. Clemons Approach to inflammatory breast cancer Can Fam Physician, January 1, 2009; 55(1): 25 - 31. [Abstract] [Full Text] [PDF]

				R. S. Mehta, T. Schubbert, and K. Kong Trastuzumab in inflammatory breast cancer Ann. Onc., October 1, 2008; 19(10): 1815 - 1817. [Full Text] [PDF]

				A. R FERRARA Inflammatory Breast Cancer: Challenges and Developments Radiol. Technol., September 1, 2008; 80(1): 49M - 60M. [Abstract] [Full Text] [PDF]